ONC Stock Price, News and Analysis
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Market Cap: $31,378,518,069.48
Industry: PHARMACEUTICAL PREPARATIONS
Track ONC stock with real-time alerts and market analysis
Current Price: $300.01
BeiGene Ltd.
$300.01
+0.33%+$1.00
Major market announcement affects tech stocks across all sectors
Earnings report shows significant growth in quarterly revenue
Regulatory changes impact industry outlook for upcoming quarter